JP2021004249A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021004249A5 JP2021004249A5 JP2020155978A JP2020155978A JP2021004249A5 JP 2021004249 A5 JP2021004249 A5 JP 2021004249A5 JP 2020155978 A JP2020155978 A JP 2020155978A JP 2020155978 A JP2020155978 A JP 2020155978A JP 2021004249 A5 JP2021004249 A5 JP 2021004249A5
- Authority
- JP
- Japan
- Prior art keywords
- months
- composition
- hiv
- pro140
- infected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462039620P | 2014-08-20 | 2014-08-20 | |
| US62/039,620 | 2014-08-20 | ||
| US201562192941P | 2015-07-15 | 2015-07-15 | |
| US62/192,941 | 2015-07-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529600A Division JP6767367B2 (ja) | 2014-08-20 | 2015-08-20 | 代替処置としてのｈｉｖ抗体療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021004249A JP2021004249A (ja) | 2021-01-14 |
| JP2021004249A5 true JP2021004249A5 (https=) | 2021-02-25 |
| JP7035143B2 JP7035143B2 (ja) | 2022-03-14 |
Family
ID=55351264
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529600A Expired - Fee Related JP6767367B2 (ja) | 2014-08-20 | 2015-08-20 | 代替処置としてのｈｉｖ抗体療法 |
| JP2020155978A Expired - Fee Related JP7035143B2 (ja) | 2014-08-20 | 2020-09-17 | 代替処置としてのｈｉｖ抗体療法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529600A Expired - Fee Related JP6767367B2 (ja) | 2014-08-20 | 2015-08-20 | 代替処置としてのｈｉｖ抗体療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10562969B2 (https=) |
| EP (2) | EP3183270B1 (https=) |
| JP (2) | JP6767367B2 (https=) |
| KR (1) | KR20170042706A (https=) |
| CN (1) | CN106661113A (https=) |
| AU (2) | AU2015305401A1 (https=) |
| BR (1) | BR112017003252A2 (https=) |
| CA (1) | CA2957817A1 (https=) |
| ES (1) | ES2880950T3 (https=) |
| MX (1) | MX2017002093A (https=) |
| WO (1) | WO2016029049A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107847514A (zh) | 2015-06-23 | 2018-03-27 | 西托戴恩股份有限公司 | 炎症、癌症、自身免疫和其它病症中ccl5配体结合ccr5受体的抑制作用和ccr5/ccl5轴信号传导的改变 |
| CN111886249A (zh) * | 2017-09-18 | 2020-11-03 | 西托戴恩股份有限公司 | 用于鉴定和治疗适合长期抗-ccr5剂治疗的hiv-1感染患者亚群的筛选方法 |
| WO2024008177A1 (en) * | 2022-07-08 | 2024-01-11 | Nanjing Curegene Technology Co., Ltd. | Engineered cells and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7122185B2 (en) * | 2002-02-22 | 2006-10-17 | Progenics Pharmaceuticals, Inc. | Anti-CCR5 antibody |
| RU2353357C2 (ru) * | 2003-05-16 | 2009-04-27 | Юниверсити Оф Мэрилэнд Байотекнолоджи Инститьют | Композиции для супрессии экспрессии ccr5 и способы их применения |
| CN101495145A (zh) * | 2005-07-22 | 2009-07-29 | 原基因药物有限公司 | 用于减少受hiv-1感染的患者中病毒负荷的方法 |
| EP2150817A4 (en) * | 2007-04-30 | 2011-09-07 | Progenics Pharm Inc | PROCEDURE FOR REDUCING VIRUS LOAD IN HIV-1 INFECTED PATIENTS |
| US10500274B2 (en) * | 2008-04-30 | 2019-12-10 | Cytodyn Inc. | Methods for reducing viral load in HIV-1 infected patients |
| NZ602685A (en) * | 2010-03-01 | 2014-10-31 | Cytodyn Inc | Concentrated protein formulations and uses thereof |
-
2015
- 2015-08-20 CA CA2957817A patent/CA2957817A1/en not_active Abandoned
- 2015-08-20 JP JP2017529600A patent/JP6767367B2/ja not_active Expired - Fee Related
- 2015-08-20 EP EP15832985.4A patent/EP3183270B1/en active Active
- 2015-08-20 KR KR1020177007086A patent/KR20170042706A/ko not_active Ceased
- 2015-08-20 CN CN201580044550.6A patent/CN106661113A/zh active Pending
- 2015-08-20 ES ES15832985T patent/ES2880950T3/es active Active
- 2015-08-20 AU AU2015305401A patent/AU2015305401A1/en not_active Abandoned
- 2015-08-20 BR BR112017003252A patent/BR112017003252A2/pt not_active Application Discontinuation
- 2015-08-20 US US15/504,928 patent/US10562969B2/en not_active Expired - Fee Related
- 2015-08-20 MX MX2017002093A patent/MX2017002093A/es unknown
- 2015-08-20 WO PCT/US2015/046160 patent/WO2016029049A1/en not_active Ceased
- 2015-08-20 EP EP21166771.2A patent/EP3904390A1/en not_active Withdrawn
-
2020
- 2020-01-08 US US16/737,291 patent/US20200385475A1/en not_active Abandoned
- 2020-09-17 JP JP2020155978A patent/JP7035143B2/ja not_active Expired - Fee Related
-
2021
- 2021-04-07 AU AU2021202132A patent/AU2021202132A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7559175B2 (ja) | Ｈｉｖおよびエイズの治療および予防方法 | |
| JP2023553393A (ja) | うつ病患者の自殺リスク低減のためのブプロピオンおよびデキストロメトルファン | |
| Kemper et al. | Mexiletine for HIV-infected patients with painful peripheral neuropathy: a double-blind, placebo-controlled, crossover treatment trial | |
| JP6353577B2 (ja) | 組み合わせ組成物 | |
| JP2021004249A5 (https=) | ||
| JP2022062170A5 (https=) | ||
| JP2018513188A5 (https=) | ||
| IL292706A (en) | Type i interferon inhibition in systemic lupus erythematosus | |
| Wedemeyer et al. | 96 weeks of pegylated-Interferon-alpha-2a plus tenofovir or placebo for the treatment of hepatitis delta: the HIDIT-2 study: 31 | |
| JP2022550828A5 (https=) | ||
| CN112996517A (zh) | 预防hiv的整合酶抑制剂 | |
| EP3393517B1 (en) | Acetylsalicylic acid for use in the treatment of moderate to severe influenza | |
| JP2005529152A5 (https=) | ||
| PH12014000275A1 (en) | Antiviral pharmaceutical formulation for the effective treatment of dengue, influenza and hiv/aids | |
| JP2019038858A (ja) | ペマフィブラートを含有する医薬 | |
| Yakubova et al. | Safety and PK study of VM-1500A-LAI, a novel long-acting injectable therapy for HIV | |
| RU2840191C1 (ru) | Способ лечения пациентов с вич-инфекцией | |
| JP2022538449A5 (https=) | ||
| JP2022538338A5 (https=) | ||
| Elliott et al. | Cabotegravir extended-release and rilpivirine injectable suspension (Cabenuva) and cabotegravir tablets (Vocabria) | |
| WO2014037121A1 (en) | Use of rifapentine in the treatment of tuberculosis in patients infected with the human immunodeficiency virus (hiv) / acquired immune deficiency syndrome (aids) and treated with an antiretroviral combination | |
| JP2019508399A (ja) | 多くの治療を経験したｈｉｖ−１に感染した個体において使用するためのホステムサビル | |
| Elliott et al. | Fostemsavir extended-release tablets (Rukobia) | |
| Rizza et al. | Novel HIV drugs and drug delivery strategies. A report from the 2018 Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts, USA-March 4-7, 2018 | |
| CN117017986A (zh) | 康替唑胺在制备抗结核病药物中的应用 |